Peptides/Recovery and injury
TB-500
Also sold as Thymosin Beta-4, TB4
BPC-157's usual partner in a recovery stack, built on genuinely interesting wound-repair biology and a long animal record.
At a glance
What people use it for
- Soft tissue injuries, often stacked with BPC-157
- Recovery from heavy training
- Marketed for flexibility and range of movement
How it is taken
Sold as a powder for injection, usually reconstituted and injected under the skin.
Evidence
No human trials yet
Best known for
- Based on thymosin beta-4, a repair protein the body already makes
- Works on actin, the scaffolding that lets cells move to an injury
- The most common partner to BPC-157 in a recovery stack
- The full protein has been through human trials for eye and skin wounds
TB-500 is a synthetic version of part of thymosin beta-4, a protein your body makes that is involved in cell movement and wound repair. In practice it is sold as the partner to BPC-157, and the two are very often bought together.
The distinction between TB-500 and thymosin beta-4 itself is the most useful thing to understand about it, and it is where most of the confusion starts.
Why people are talking about it
The mechanism is unusually easy to picture. Thymosin beta-4 regulates actin, the protein that gives cells their internal scaffolding and lets them move. Cells that can move can reach an injury. A compound that helps repair cells arrive sooner and in greater numbers is an intuitive proposition.
The second reason is company. It is almost always bought alongside BPC-157, and the pairing has become the default recovery stack people hear about first.
What people take it for
Soft tissue injuries and general recovery. The pitch is that it helps cells migrate to the site of damage and encourages new blood vessels to form there, which is a fair description of the underlying biology.
Soft tissue healing
The claim is that a strained muscle or a damaged tendon knits back together faster, and the mechanism offered is actin binding.
What that would look like to a person is repair cells arriving at the damage sooner. That has been described in cell culture and in animal wound models.
Blood vessel growth
The second claim is that new vessels grow into damaged tissue, bringing oxygen and materials with them. Angiogenesis is the body building new plumbing to an area that has lost its supply, and thymosin beta-4 is genuinely involved in it.
This has been measured in animals and in cell work.
Flexibility and range of movement
Marketing frequently claims improved flexibility. There is no mechanism specific to this that has been demonstrated, and no study has measured range of movement as an outcome. It appears to have arrived from user reports rather than from research.
What the evidence shows
The underlying protein is real and genuinely does the things described, in cell cultures and in animals. Thymosin beta-4 itself has been through human trials for eye surface injuries and for pressure ulcers, with mixed results.
What does not yet exist is a completed human trial showing that injecting TB-500 shortens recovery from a torn hamstring or a stubborn tendon.
There is a further wrinkle worth knowing. Thymosin beta-4 is a 43-amino-acid protein; what is sold as TB-500 is generally a short fragment of it, and the two are not interchangeable. Two vials both labelled TB-500 may contain different fragments, and the label rarely says which.
How it is taken
Protocols circulating online describe a loading period of twice-weekly subcutaneous injections followed by a lower maintenance frequency.
Those schedules were not derived from a trial. They trace back to vendor documentation and accumulated community practice, and they are reported here because readers encounter them. Our guide to reconstituting a peptide vial covers the mechanics of mixing one.
How it compares
Against BPC-157
BPC-157 is the usual partner and has a similar profile: substantial animal work, no completed human efficacy trial. Because the two are almost always used together, anyone reporting a benefit cannot say which compound produced it.
Against thymosin beta-4
The full protein has been through real human trials and is the compound the credible research was done with. The fragment sold as TB-500 is cheaper, easier to make, and much less studied.
Common questions
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is the full protein and the one used in the human trials people cite. TB-500 is generally a short fragment of it.
Does it work for injuries?
No completed human trial has measured that. The animal and cell data is real, and it is not the same thing.
Why is it always sold with BPC-157?
The two are marketed together as a healing stack. The practical consequence is that no user can attribute an effect to either one.
Is it detectable in a drug test?
Yes, and it has produced sanctions in both human and equine sport, so anyone subject to testing should know that.
Last reviewed .